Literature DB >> 33632296

Interplay between severities of COVID-19 and the gut microbiome: implications of bacterial co-infections?

Jyoti Chhibber-Goel1, Sreehari Gopinathan1, Amit Sharma2.   

Abstract

COVID-19 is an acute respiratory distress syndrome and is often accompanied by gastrointestinal symptoms. The SARS-CoV-2 has been traced not only in nasopharyngeal and mid-nasal swabs but also in stool and rectal swabs of COVID-19 patients. The gut microbiota is important for an effective immune response as it ensures that unfavorable immune reactions in lungs and other vital organs are regulated. The human gut-lung microbiota interplay provides a framework for therapies in the treatment and management of several pulmonary diseases and infections. Here, we have collated data from COVID-19 studies, which suggest that bacterial co-infections as well as the gut-lung cross talk may be important players in COVID-19 disease prognosis. Our analyses suggests a role of gut microbiome in pathogen infections as well as in an array of excessive immune reactions during and post COVID-19 infection recovery period.

Entities:  

Keywords:  Angiotensin-converting enzyme 2; Gut-lung axis; Gut-microbiome; Opportunistic pathogens; Probiotics; SARS-CoV-2

Year:  2021        PMID: 33632296      PMCID: PMC7906082          DOI: 10.1186/s13099-021-00407-7

Source DB:  PubMed          Journal:  Gut Pathog        ISSN: 1757-4749            Impact factor:   5.324


  52 in total

1.  Microbiota-dependent signals are required to sustain TLR-mediated immune responses.

Authors:  Lehn K Weaver; Danielle Minichino; Chhanda Biswas; Niansheng Chu; Jung-Jin Lee; Kyle Bittinger; Sabrin Albeituni; Kim E Nichols; Edward M Behrens
Journal:  JCI Insight       Date:  2019-01-10

Review 2.  Ringing bells: Morganella morganii fights for recognition.

Authors:  Altaf Bandy
Journal:  Public Health       Date:  2020-03-11       Impact factor: 2.427

3.  Probiotic prophylaxis of ventilator-associated pneumonia: a blinded, randomized, controlled trial.

Authors:  Lee E Morrow; Marin H Kollef; Thomas B Casale
Journal:  Am J Respir Crit Care Med       Date:  2010-06-03       Impact factor: 21.405

4.  Targeting the degradation of angiotensin II with recombinant angiotensin-converting enzyme 2: prevention of angiotensin II-dependent hypertension.

Authors:  Jan Wysocki; Minghao Ye; Eva Rodriguez; Francisco R González-Pacheco; Clara Barrios; Karla Evora; Manfred Schuster; Hans Loibner; K Bridget Brosnihan; Carlos M Ferrario; Josef M Penninger; Daniel Batlle
Journal:  Hypertension       Date:  2009-11-30       Impact factor: 10.190

5.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.

Authors:  Chaolin Huang; Yeming Wang; Xingwang Li; Lili Ren; Jianping Zhao; Yi Hu; Li Zhang; Guohui Fan; Jiuyang Xu; Xiaoying Gu; Zhenshun Cheng; Ting Yu; Jiaan Xia; Yuan Wei; Wenjuan Wu; Xuelei Xie; Wen Yin; Hui Li; Min Liu; Yan Xiao; Hong Gao; Li Guo; Jungang Xie; Guangfa Wang; Rongmeng Jiang; Zhancheng Gao; Qi Jin; Jianwei Wang; Bin Cao
Journal:  Lancet       Date:  2020-01-24       Impact factor: 79.321

6.  Angiotensin-converting enzyme 2 protects from severe acute lung failure.

Authors:  Yumiko Imai; Keiji Kuba; Shuan Rao; Yi Huan; Feng Guo; Bin Guan; Peng Yang; Renu Sarao; Teiji Wada; Howard Leong-Poi; Michael A Crackower; Akiyoshi Fukamizu; Chi-Chung Hui; Lutz Hein; Stefan Uhlig; Arthur S Slutsky; Chengyu Jiang; Josef M Penninger
Journal:  Nature       Date:  2005-07-07       Impact factor: 49.962

7.  Alterations in Gut Microbiota of Patients With COVID-19 During Time of Hospitalization.

Authors:  Tao Zuo; Fen Zhang; Grace C Y Lui; Yun Kit Yeoh; Amy Y L Li; Hui Zhan; Yating Wan; Arthur C K Chung; Chun Pan Cheung; Nan Chen; Christopher K C Lai; Zigui Chen; Eugene Y K Tso; Kitty S C Fung; Veronica Chan; Lowell Ling; Gavin Joynt; David S C Hui; Francis K L Chan; Paul K S Chan; Siew C Ng
Journal:  Gastroenterology       Date:  2020-05-20       Impact factor: 33.883

8.  Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus.

Authors:  Wenhui Li; Michael J Moore; Natalya Vasilieva; Jianhua Sui; Swee Kee Wong; Michael A Berne; Mohan Somasundaran; John L Sullivan; Katherine Luzuriaga; Thomas C Greenough; Hyeryun Choe; Michael Farzan
Journal:  Nature       Date:  2003-11-27       Impact factor: 49.962

Review 9.  Lung microbiome and coronavirus disease 2019 (COVID-19): Possible link and implications.

Authors:  Saroj Khatiwada; Astha Subedi
Journal:  Hum Microb J       Date:  2020-08-05
View more
  13 in total

Review 1.  Altered gut microbiota patterns in COVID-19: Markers for inflammation and disease severity.

Authors:  Chiranjib Chakraborty; Ashish Ranjan Sharma; Manojit Bhattacharya; Kuldeep Dhama; Sang-Soo Lee
Journal:  World J Gastroenterol       Date:  2022-07-07       Impact factor: 5.374

Review 2.  Gut microbiota in COVID-19: key microbial changes, potential mechanisms and clinical applications.

Authors:  Raphaela I Lau; Fen Zhang; Qin Liu; Qi Su; Francis K L Chan; Siew C Ng
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2022-10-21       Impact factor: 73.082

Review 3.  Mucormycosis and COVID-19-Associated Mucormycosis: Insights of a Deadly but Neglected Mycosis.

Authors:  Laura C García-Carnero; Héctor M Mora-Montes
Journal:  J Fungi (Basel)       Date:  2022-04-25

Review 4.  Cross-talk between immune system and microbiota in COVID-19.

Authors:  Shaghayegh Baradaran Ghavami; Mahsa Pourhamzeh; Maryam Farmani; Shahrbanoo Keshavarz Azizi Raftar; Shabnam Shahrokh; Anastasia Shpichka; Hamid Asadzadeh Aghdaei; Mojdeh Hakemi-Vala; Nikoo Hossein-Khannazer; Peter Timashev; Massoud Vosough
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2021-11-02       Impact factor: 4.095

Review 5.  Gut and airway microbiota and their role in COVID-19 infection and pathogenesis: a scoping review.

Authors:  Tik Fung Dave Liu; Elena Philippou; Ourania Kolokotroni; Georgios Siakallis; Kenan Rahima; Constantina Constantinou
Journal:  Infection       Date:  2021-10-20       Impact factor: 7.455

Review 6.  COVID-19 associated mucormycosis: evolving technologies for early and rapid diagnosis.

Authors:  Rachel Samson; Mahesh Dharne
Journal:  3 Biotech       Date:  2021-12-06       Impact factor: 2.893

Review 7.  An insight to the therapeutic potential of algae-derived sulfated polysaccharides and polyunsaturated fatty acids: Focusing on the COVID-19.

Authors:  Kobra Ziyaei; Zahra Ataie; Majid Mokhtari; Kelvin Adrah; Mohammad Ali Daneshmehr
Journal:  Int J Biol Macromol       Date:  2022-03-16       Impact factor: 8.025

8.  Diagnostic, Prognostic, and Therapeutic Roles of Gut Microbiota in COVID-19: A Comprehensive Systematic Review.

Authors:  Yeganeh Farsi; Azin Tahvildari; Mahta Arbabi; Fateme Vazife; Leonardo A Sechi; Amir Hashem Shahidi Bonjar; Parnian Jamshidi; Mohammad Javad Nasiri; Mehdi Mirsaeidi
Journal:  Front Cell Infect Microbiol       Date:  2022-03-04       Impact factor: 5.293

Review 9.  Role of ethno-phytomedicine knowledge in healthcare of COVID-19: advances in traditional phytomedicine perspective.

Authors:  Md Nasir Ahmed; Kerry Hughes
Journal:  Beni Suef Univ J Basic Appl Sci       Date:  2022-08-04

Review 10.  Implications of COVID-19 Pandemic on the Emergence of Antimicrobial Resistance: Adjusting the Response to Future Outbreaks.

Authors:  Doris Rusic; Marino Vilovic; Josipa Bukic; Dario Leskur; Ana Seselja Perisin; Marko Kumric; Dinko Martinovic; Ana Petric; Darko Modun; Josko Bozic
Journal:  Life (Basel)       Date:  2021-03-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.